Kairos Pharma reports news as a clinical-stage biopharmaceutical company developing cancer therapeutics designed to address drug resistance and immune suppression. Its updates center on ENV-105, also described as carotuximab, a CD105-targeting antibody program studied in prostate cancer and non-small cell lung cancer, along with broader oncology pipeline and structural-biology themes.
Company news also covers scientific conference presentations, clinical-data disclosures, annual meeting and shareholder matters, award recognition, and annual filing updates. Kairos has stated that ENV-105 has not been approved as safe or effective by the FDA or comparable foreign regulators.
Kairos Pharma (NYSE American: KAPA) has published peer-reviewed research revealing a potential breakthrough in treating drug resistance in non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, demonstrates that CD105 (endoglin) plays a important role in resistance to osimertinib, a frontline NSCLC treatment.
The research shows that ENV105 (carotuximab), a CD105-neutralizing antibody, successfully restored treatment sensitivity to EGFR-targeted therapies in preclinical models. The combination of osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility.
The global NSCLC treatment market is projected to reach $45 billion by 2030. Kairos Pharma is currently conducting clinical trials to evaluate this therapy in EGFR-driven lung cancer patients.
Kairos Pharma (NYSE: KAPA) presented preclinical data on two investigational compounds at the AACR IO conference in Los Angeles (Feb 23-26, 2025). The first compound, KROS 101, a GITR agonist, showed significant tumor growth inhibition in melanoma models and demonstrated superior anti-tumor activity compared to TRX518. It increased helper and cytotoxic T cell proliferation while preventing T cell exhaustion in tumors.
The second compound, KROS 401, a peptide inhibitor, showed promise in reprogramming macrophages to inhibit tumor growth. Studies revealed anti-tumor effects in glioma-bearing mice by decreasing M2 macrophages that typically facilitate tumor growth. The research indicates potential therapeutic applications for both melanoma and glioblastoma treatment.
Kairos Pharma (NYSE American: KAPA) announces that its academic partner Cedars-Sinai Medical Center has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205.
ENV205 is a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. The drug targets key pathways driving cachexia, a severe muscle-wasting condition affecting over half of cancer patients, characterized by involuntary weight loss, muscle atrophy, and systemic inflammation.
The funding will accelerate research efforts through the company's ongoing partnership with Cedars-Sinai Medical Center, aiming to advance the therapy toward clinical trials.
Kairos Pharma (NYSE American: KAPA) announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah as a new site for its Phase 2 clinical trial of ENV105 in castrate-resistant prostate cancer patients. The randomized trial compares apalutamide alone versus apalutamide+ENV105 combination therapy. The study, supported by Kairos and the National Cancer Institute, aims to identify blood markers that could help select patients who would benefit most from ENV105 treatment.
ENV105 is being developed to address resistance in various cancers as they become resistant to standard treatments. The addition of Huntsman, a renowned cancer center, is expected to enable testing ENV105 in a broader patient population while adding credibility to the study within the medical community.
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS101, at the AACR-JCA Joint Conference. The research demonstrated KROS101's effectiveness in enhancing T cell infiltration, proliferation, and cancer cell-killing abilities in melanoma mouse models and human glioblastoma in vitro.
The compound showed significant results in reducing melanoma tumors in human GITR knock-in mouse models, outperforming the GITR antibody TRX518. KROS101 works by stabilizing the active form of GITRL, reducing suppressive T-cells while enhancing cytotoxic T cells. The presentation highlighted the compound's potential as a novel cancer therapy, particularly for melanoma and glioblastoma treatment.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the 13th AACR-JCA Joint Conference in Maui, Hawaii. The clinical-stage biopharmaceutical company will present a talk titled 'KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment' during the plenary session on February 5, 2025, at 4:00 PM local time.
The conference, 'From Cancer Discovery Science to Therapeutic Innovation,' scheduled for February 1-5, 2025, is jointly organized by the American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA). This prestigious meeting series brings together leading researchers from the United States, Japan, and worldwide to share findings and present latest advances in basic, translational, and clinical cancer research.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, shared an update on its business milestones for 2024 and the outlook for 2025.
Key highlights from 2024:
- Closing of the Initial Public Offering and listing on the NYSE American on September 16, 2024.
- Agreement with PreCheck Health Services to develop a biomarker panel for ENV105 targeting cancer drug resistance in prostate and lung cancer.
- Addition of City of Hope Cancer Center to the Phase 2 trial of ENV105 for castrate-resistant prostate cancer.
- First patient dosed in combination therapy of ENV105 and Osimertinib for EGFR-driven lung cancer.
- Initiation of research coverage by EF Hutton and Rodman and Renshaw.
For 2025, Kairos expects:
- Continuation of Phase 2 and Phase 1 trials of ENV105 in prostate and non-small cell lung cancer, respectively.
- Safety data readouts for both trials, with prostate cancer data expected in the first half of 2025 and NSCLC data by year-end.
- Pre-IND studies of KROS 101 and initiation of partnering discussions.
The company raised $3.5 million through a PIPE transaction and expanded patent coverage to protect their technologies. Kairos aims to provide significant shareholder value through continued development and presentation of their clinical data.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming Lytham Partners Investor Healthcare Summit, scheduled for January 13, 2025. The company's leadership, including CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick, will deliver a corporate overview during a virtual presentation at 2:00 PM ET.
The management team will be available for one-on-one virtual meetings throughout the event. Interested parties can arrange meetings through Lytham Partners or register directly via the event website. The presentation will be accessible through a webcast, with replay options available after the event.
Kairos Pharma (NYSE American:KAPA), a clinical stage biotechnology company, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. During the conference, the company's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Kairos Pharma (NYSE American: KAPA) announces the addition of City of Hope Cancer Center in Duarte, California to its Phase 2 clinical trial for ENV105 in castrate-resistant prostate cancer patients. The trial will compare apalutamide alone versus apalutamide+ENV105 combination therapy. This is the first of several planned new centers to be added. The expansion aims to test ENV105 in a broader patient population and identify blood markers for patient selection. The trial is supported by Kairos Pharma and a National Cancer Institute grant. Preclinical findings indicate ENV105 blocks hormone therapy resistance mechanisms.